CCHT(SZ:000661) Zheng Quan Shi Bao Wang·2025-09-08 10:03Group 1 - The core point of the article is that Changchun High New Technology Industry Group Co., Ltd. announced that its subsidiary, Jinsai Pharmaceutical, has received the acceptance notice from the National Medical Products Administration for the clinical trial application of GS3-007a dry suspension, which is intended for treating growth retardation in children due to endogenous growth hormone deficiency [1] Group 2 - The drug GS3-007a is specifically aimed at addressing the issue of growth retardation in children, indicating a targeted therapeutic approach in the pediatric market [1] - The acceptance of the clinical trial application marks a significant step in the drug development process, potentially leading to future commercialization if trials are successful [1] - This development reflects the ongoing efforts within the pharmaceutical industry to innovate and provide solutions for unmet medical needs, particularly in pediatric healthcare [1]